Amarin Corp Plc (AMRN)

[Dancing in the dark]

When the inevitable generic infringement on RIt happens, what can we do? Who is liable for it?

instead of focusing litigation on whether or not the generic manufacturers are actively PROMOTING their “skinny labeled” generic for patent-protected reduce-it IP uses,

the argument could be made that by PRODUCING generic icosapent ethyl in a quantity in excess of that required to fulfill Rxs to treat the MARINE indication, the generic manufacturers are inducing infringement on the reduce-it IP.